Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.37 |
| ▸ | HRH2 | P25021 | 8/20 | 0.37 |
| ▸ | NOS3 | P29474 | 5/20 | 0.35 |
| ▸ | NOS1 | P29475 | 5/20 | 0.35 |
| ▸ | NOS2 | P35228 | 5/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688215 | 0.81 | CXCR4 (0.37) | HRH3HRH2NOS3NOS1NOS2 | |
| SCHEMBL20851571 | 0.81 | CXCR4 (0.37) | HRH3HRH2NOS3NOS1NOS2 | |
| SCHEMBL12346329 | 0.81 | CXCR4 (0.37) | HRH3HRH2NOS3NOS1NOS2 | |
| SCHEMBL20851269 | 0.79 | HRH3 (0.38) | HRH3HRH2 | |
| SCHEMBL22275573 | 0.79 | HRH3 (0.38) | HRH3HRH2 | |
| SCHEMBL20851248 | 0.79 | HRH3 (0.38) | HRH3HRH2 | |
| SCHEMBL12696397 | 0.79 | ACHE (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL22275748 | 0.79 | HRH3 (0.38) | HRH3HRH2 | |
| SCHEMBL31378836 | 0.79 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL20851239 | 0.78 | HRH3 (0.41) | HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | HRH3 76/4885HRH2 24/4885NOS3 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.